Viridian Therapeutics, Inc.\DE (VRDN) Cost of Revenue (2016)
Historic Cost of Revenue for Viridian Therapeutics, Inc.\DE (VRDN) over the last 3 years, with Q4 2016 value amounting to $692000.0.
- Viridian Therapeutics, Inc.\DE's Cost of Revenue rose 2744.01% to $692000.0 in Q4 2016 from the same period last year, while for Dec 2016 it was $2.5 million, marking a year-over-year decrease of 824.63%. This contributed to the annual value of $2.5 million for FY2016, which is 42.99% down from last year.
- As of Q4 2016, Viridian Therapeutics, Inc.\DE's Cost of Revenue stood at $692000.0, which was up 2744.01% from $599000.0 recorded in Q3 2016.
- Viridian Therapeutics, Inc.\DE's 5-year Cost of Revenue high stood at $954000.0 for Q2 2014, and its period low was $543000.0 during Q4 2015.
- Moreover, its 3-year median value for Cost of Revenue was $711500.0 (2014), whereas its average is $724250.0.
- Its Cost of Revenue has fluctuated over the past 5 years, first crashed by 3047.38% in 2015, then skyrocketed by 2744.01% in 2016.
- Quarter analysis of 3 years shows Viridian Therapeutics, Inc.\DE's Cost of Revenue stood at $781000.0 in 2014, then tumbled by 30.47% to $543000.0 in 2015, then increased by 27.44% to $692000.0 in 2016.
- Its Cost of Revenue stands at $692000.0 for Q4 2016, versus $599000.0 for Q3 2016 and $628000.0 for Q2 2016.